HUMHumana Inc.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Bruce D. Broussard

Location

Kentucky, USA

Exchange

NYSE

Website

https://humana.com

Summary

Humana Inc.

Company Info

CEO

Bruce D. Broussard

Location

Kentucky, USA

Exchange

NYSE

Website

https://humana.com

Summary

Humana Inc.

AI Insights for HUM
5 min read

Quick Summary

Humana Inc. is a U.S.-based health insurance and healthcare services company headquartered in Louisville, Kentucky. The company operates through Retail, Group and Specialty, and Healthcare Services segments, serving millions of members through medical benefit plans. Its core business is Medicare Advantage, where it is considered a major industry leader and has significant exposure to U.S. government reimbursement policy. Humana also provides pharmacy benefit management, primary care, home health, and related healthcare services through its CenterWell platform. Its main customers include Medicare-eligible seniors, employer groups, individuals, Medicaid members, and government-sponsored healthcare beneficiaries.

Strengths

•

Humana’s primary strength is its leading position in Medicare Advantage, a large and growing market supported by the aging U.S. population.

•

The company has significant scale, with tens of millions of medical benefit members referenced historically and a current workforce of about 67,100 employees.

•

Its CenterWell healthcare services platform gives it vertical capabilities in primary care, home care, pharmacy, and care management.

•

These services can help Humana improve outcomes, manage utilization, and deepen relationships with members.

•

The company also benefits from strong revenue scale, recognizable branding in senior healthcare, and analyst sentiment that remains moderately constructive despite recent stock weakness.

Key Risks

•

The most significant risk for Humana is regulatory pressure, especially changes to Medicare Advantage reimbursement, risk adjustment, and Star-rating methodology.

•

A flat or minimal CMS payment increase could squeeze margins if medical costs continue rising.

•

The company also faces intense competition from UnitedHealth, CVS, Cigna, Elevance, Centene, and other managed-care firms.

•

Legal scrutiny and political focus on government-funded healthcare programs could create additional compliance costs or business restrictions.

What to Watch

During the most recent reported period, Humana’s fundamentals show operating revenue of about $40.87 billion, total gross profit of about $5.50 billion, operating income of about $1.36 billion, and net income of about $693 million.
The company continued operating as a major health insurer and healthcare services provider with approximately 67,100 employees and a large Medicare-oriented member base.
Recent news highlighted that Humana has been investing heavily in medical costs, transformation initiatives, and margin restoration efforts.
Medicare Advantage enrollment reportedly increased by about 1 million, and management has indicated expectations for continued membership growth into 2026.
However, the quarter was also overshadowed by concerns about Star ratings, reimbursement pressure, higher medical costs, and the market reaction to proposed Medicare Advantage payment updates.

Price Drivers

•

Humana’s stock price is being driven primarily by Medicare Advantage reimbursement expectations, medical cost trends, membership growth, and earnings guidance.

•

Recent news indicates the shares fell sharply after CMS proposed only a 0.09% Medicare Advantage payment increase for 2027, far below the 4% to 6% increase investors had expected.

•

That proposal raised concerns about margin pressure because Humana has heavy exposure to Medicare Advantage and rising healthcare utilization costs.

•

Earnings are also a major driver, with 2025 adjusted EPS reportedly above initial guidance but 2026 adjusted EPS guidance expected to fall significantly because of a Stars-rating headwind.

•

Valuation metrics such as a price-to-earnings ratio near 38.79, an earnings yield of about 2.58%, and EV-to-EBITDA near 12.29 suggest investors are weighing long-term recovery potential against near-term profitability pressure.

Recent News

•

Recent news about Humana has been mixed, with strong membership growth and long-term opportunity offset by serious margin and reimbursement concerns.

•

One report noted that Humana’s stock was down more than 30% year to date and 43% from its 52-week high, even though analysts rated it Moderate Buy with a target implying upside.

•

Another report said Humana produced 2025 adjusted EPS of $17.14, above initial guidance, but that a $3.5 billion Stars-rating headwind would reduce 2026 adjusted EPS guidance to at least $9.

•

A major negative catalyst was the report that shares plunged more than 21% after CMS proposed only a 0.09% Medicare Advantage payment increase for 2027.

•

Other news highlighted Humana’s strengths in Medicare Advantage, CenterWell, and service expansion, while warning about medical costs, debt, legal scrutiny, regulatory pressure, and competition.

Market Trends

•

The broader healthcare market is being shaped by an aging population, rising medical utilization, government reimbursement pressure, and growing demand for integrated care models.

•

Medicare Advantage remains a large long-term growth market, but it is becoming more politically and financially sensitive as federal spending scrutiny increases.

•

Managed-care companies are increasingly investing in primary care, home health, pharmacy benefit management, and data-driven care coordination to control costs and improve outcomes.

•

At the same time, higher medical costs and lower-than-expected reimbursement updates are pressuring margins across insurers.

•

Investors may favor diversified healthcare exposure through broad healthcare ETFs or companies with less direct Medicare Advantage concentration if policy uncertainty remains elevated.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on HUM

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@kewur 9 months ago

Market recap: Hot jobs report, earnings misses from Mattel and HOOD, and software stocks

Market recap: Hot jobs report, earnings misses from Mattel and HOOD, and software stocks

post thumbnail
avatar
@Zalotie 9 months ago

Health insurers facing headwinds from Medicare rates and new PBM regulations

Health insurers facing headwinds from Medicare rates and new PBM regulations

post thumbnail
avatar
@UndyingValue 9 months ago

Market mixed as UnitedHealth tanks the Dow while S&P hits record high

Market mixed as UnitedHealth tanks the Dow while S&P hits record high

post thumbnail
avatar
@Zalotie 9 months ago

UnitedHealth drops 20% on first revenue decline forecast in decades

UnitedHealth drops 20% on first revenue decline forecast in decades

post thumbnail
avatar
@ProduceCut309 10 months ago

Obamacare Subsidy Extension Stalls

Obamacare Subsidy Extension Stalls

Momentum is fading on efforts to revive enhanced Obamacare subsidies as open enrollment wraps up. With Congress leaving town and no deal in sight, higher premiums could pressure enrollment numbers and ripple through the healthcare space. Insurers and managed care names like , , , may see shifting dynamics if fewer people stay covered, while hospitals could also feel downstream effects if coverage gaps widen. Do you think lawmakers step in later with a fix, or is the market already pricing in a prolonged subsidy gap?

avatar
@Theta_collctv 11 months ago

UNH valuation update: trading at 18.5x earnings with mixed outlook

UNH valuation update: trading at 18.5x earnings with mixed outlook

post thumbnail
avatar
@Zalotie 11 months ago

Medicare Advantage insurers getting $86B for perks that members often don't use

Medicare Advantage insurers getting $86B for perks that members often don't use

post thumbnail
avatar
@ceffenberg 2 years ago

Humana vs United Health

Humana vs United Health

UNH stock has seen extremely strong gains of 50% from levels of $350 in early January 2021 to around $525 now, while HUM stock has witnessed gains of 10% from levels of $410 to $460 over the same period.

Hum has better revenue increase but UNH is more profitable, and a good dividend as a plus.

Which one would you pick and why? 

 

No more topics to show